Orexo announces that the condition for early redemption of its existing bonds has been fulfilled

BY PR Newswire | CORPORATE | 04/02/24 07:23 AM EDT

UPPSALA,?Sweden, April 2, 2024 /PRNewswire/ -- On March 13, 2024,?Orexo AB (publ),?("Orexo (ORXOF)" or the "Company")?(STO:ORX) ?announced that the Company intends to redeem early the Company's existing senior unsecured bonds with maturity in February 2025 (ISIN SE0015193958) (the "Existing Bonds").

The early redemption was conditional upon that settlement of the Company's issue of new senior secured social bonds with a tenor of four years has occurred, which is further described in the Company's press release on March 13, 2024. This condition has been fulfilled and the early redemption is therefore no longer conditional. Hence, the early redemption will occur on?April 11, 2024, and the redemption amount will be paid to each person who is registered as owner of Existing Bonds in the debt register maintained by Euroclear Sweden at the end of business on April 4, 2024.

For further information on the early redemption, see the Company's press release on March 13, 2024, and the notice of early redemption which is available on the Company's website.

For further information please contact:

Nikolaj S?rensen, President and CEO
Fredrik J?rrsten, EVP and CFO
Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
E-mail: ir@orexo.com

About Orexo (ORXOF)

Orexo (ORXOF) is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo (ORXOF) provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo (ORXOF) is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.

For more information about Orexo (ORXOF) please visit www.orexo.com. You can also follow Orexo (ORXOF) on X, LinkedIn, and YouTube.

The information was sent for publication, through the agency of the contact person set out above, on April 2, 2024, at 1.15 pm CET.

This information was brought to you by Cision http://news.cision.com


The following files are available for download:


Orexo PR_The condition for early redemption of its existing bonds fulfilled April 2 2024


Cision View original content:https://www.prnewswire.com/news-releases/orexo-announces-that-the-condition-for-early-redemption-of-its-existing-bonds-has-been-fulfilled-302105696.html


In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation risk and credit and default risks for both issuers and counterparties. Unlike individual bonds, most bond funds do not have a maturity date, so avoiding losses caused by price volatility by holding them until maturity is not possible.

Lower-quality debt securities generally offer higher yields, but also involve greater risk of default or price changes due to potential changes in the credit quality of the issuer. Any fixed income security sold or redeemed prior to maturity may be subject to loss.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.